| Literature DB >> 10430444 |
D Tanne1, V E Bates, P Verro, S E Kasner, J R Binder, S C Patel, H H Mansbach, S Daley, L R Schultz, P N Karanjia, P Scott, J M Dayno, K Vereczkey-Porter, C Benesch, D Book, W M Coplin, D Dulli, S R Levine.
Abstract
We assessed initial clinical experience with IV tissue plasminogen activator (t-PA) treatment of acute ischemic stroke in a standardized retrospective survey of hospitals with experienced acute stroke treatment systems. The incidence of symptomatic intracerebral hemorrhage (ICH) was 6% (11 of 189 patients; 95% CI 3 to 11%), similar to that in the National Institute of Neurological Disorders and Stroke (NINDS) t-PA Stroke Study. Deviations from the NINDS protocol guidelines were identified in 30% of patients (56 of 189). The incidence of symptomatic ICH was 11% among patients with protocol deviations as compared with 4% in patients who were treated according to the NINDS protocol guidelines, suggesting that strict adherence to protocol guidelines is prudent.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10430444 DOI： 10.1212/wnl.53.2.424
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910